Literature DB >> 22831763

Diagnostic utility of NMO/AQP4-IgG in evaluating CNS inflammatory disease in Thai patients.

Metha Apiwattanakul1, Thanin Asawavichienjinda, Teeratorn Pulkes, Tasanee Tantirittisak, Thiravat Hemachudha, Erika S Horta, Sarah M Jenkins, Sean J Pittock.   

Abstract

Epidemiological studies in Thailand have reported that inflammatory demyelinating diseases (IDDs) commonly affect the optic nerve and spinal cord. We investigated the diagnostic utility of aquaporin (AQP)-4-IgG testing in 31 consecutive patients evaluated for CNS IDDs in 3 academic Thai hospital neurology clinics between February 2008 and January 2009. Patients were classified into 3 clinical diagnostic groups: Neuromyelitis optica (NMO, n=10) multiple sclerosis (MS, n=5) and unclassified IDD (n=16). All sera were tested blindly by cell binding (Euroimmun) assay (CBA). Sera were also tested by indirect immunofluorescence assay (IFA) and ELISA (RSR/Kronus). After initial screening by CBA, AQP4-IgG was detected in 6 NMO patients (60%); 3 of the 4 seronegative cases were receiving immunosuppressants. AQP4-IgG was detected in 13 unclassified IDD cases (81%), but in no MS cases. Cell binding assay and ELISA were more sensitive than IFA (p=0.0004). The 81% seropositivity rate in "unclassified" patients suggests that AQP4 autoimmunity accounts for a significant proportion of Thai CNS inflammatory demyelinating disease, especially those with optic neuritis or transverse myelitis, with or without abnormal brain MRI, in whom a specific diagnosis or clear-cut treatment approach is unclear.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22831763      PMCID: PMC3423321          DOI: 10.1016/j.jns.2012.07.014

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  11 in total

1.  Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.

Authors:  P J Waters; A McKeon; M I Leite; S Rajasekharan; V A Lennon; A Villalobos; J Palace; J N Mandrekar; A Vincent; A Bar-Or; S J Pittock
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

2.  AQP4 antibody-positive Thai cases: clinical features and diagnostic problems.

Authors:  S Siritho; I Nakashima; T Takahashi; K Fujihara; N Prayoonwiwat
Journal:  Neurology       Date:  2011-08-03       Impact factor: 9.910

3.  Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.

Authors:  Sean J Pittock; Brian G Weinshenker; Claudia F Lucchinetti; Dean M Wingerchuk; John R Corboy; Vanda A Lennon
Journal:  Arch Neurol       Date:  2006-07

4.  Clinical features and clinical course of multiple sclerosis in Thai patients: a report of 50 cases.

Authors:  S Jitpimolmard; A Vejjajiva
Journal:  J Med Assoc Thai       Date:  1994-05

5.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.

Authors:  Vanda A Lennon; Dean M Wingerchuk; Thomas J Kryzer; Sean J Pittock; Claudia F Lucchinetti; Kazuo Fujihara; Ichiro Nakashima; Brian G Weinshenker
Journal:  Lancet       Date:  2004 Dec 11-17       Impact factor: 79.321

6.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

7.  Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.

Authors:  Jacqueline Palace; Maria Isabel Leite; Angela Nairne; Angela Vincent
Journal:  Arch Neurol       Date:  2010-08

8.  Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?

Authors:  Su-Hyun Kim; Woojun Kim; Xue Feng Li; In-Ja Jung; Ho Jin Kim
Journal:  Mult Scler       Date:  2012-02-21       Impact factor: 6.312

9.  Interferon-beta(1b) treatment in neuromyelitis optica.

Authors:  Masami Tanaka; Keiko Tanaka; Mika Komori
Journal:  Eur Neurol       Date:  2009-07-07       Impact factor: 1.710

Review 10.  The spectrum of neuromyelitis optica.

Authors:  Dean M Wingerchuk; Vanda A Lennon; Claudia F Lucchinetti; Sean J Pittock; Brian G Weinshenker
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182

View more
  12 in total

1.  Evaluation of aquaporin-4 antibody assays.

Authors:  Patrick J Waters; Sean J Pittock; Jeffrey L Bennett; Sven Jarius; Brian G Weinshenker; Dean M Wingerchuk
Journal:  Clin Exp Neuroimmunol       Date:  2014-04-22

Review 2.  Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.

Authors:  Sean J Pittock; Anastasia Zekeridou; Brian G Weinshenker
Journal:  Nat Rev Neurol       Date:  2021-10-28       Impact factor: 42.937

3.  Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis.

Authors:  Yujuan Jiao; James P Fryer; Vanda A Lennon; Andrew McKeon; Sarah M Jenkins; Carin Y Smith; Amy M L Quek; Brian G Weinshenker; Dean M Wingerchuk; Elizabeth A Shuster; Claudia F Lucchinetti; Sean J Pittock
Journal:  JAMA Neurol       Date:  2014-01       Impact factor: 18.302

Review 4.  Aquaporin-4 autoimmunity.

Authors:  Anastasia Zekeridou; Vanda A Lennon
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-05-21

5.  Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity.

Authors:  Francesco Pisani; Angelo Sparaneo; Carla Tortorella; Maddalena Ruggieri; Maria Trojano; Maria Grazia Mola; Grazia Paola Nicchia; Antonio Frigeri; Maria Svelto
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

6.  AQP4 autoantibody assay performance in clinical laboratory service.

Authors:  J P Fryer; V A Lennon; S J Pittock; S M Jenkins; P Fallier-Becker; S L Clardy; E Horta; E A Jedynak; C F Lucchinetti; E A Shuster; B G Weinshenker; D M Wingerchuk; A McKeon
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2014-05-22

7.  AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD.

Authors:  Kerri Prain; Mark Woodhall; Angela Vincent; Sudarshini Ramanathan; Michael H Barnett; Christine S Bundell; John D E Parratt; Roger A Silvestrini; Wajih Bukhari; Fabienne Brilot; Patrick Waters; Simon A Broadley
Journal:  Front Neurol       Date:  2019-10-04       Impact factor: 4.003

Review 8.  Update on biomarkers in neuromyelitis optica.

Authors:  Esther Melamed; Michael Levy; Patrick J Waters; Douglas Kazutoshi Sato; Jeffrey L Bennett; Gareth R John; Douglas C Hooper; Albert Saiz; Amit Bar-Or; Ho Jin Kim; Lakha Pandit; Maria Isabel Leite; Nasrin Asgari; Najib Kissani; Rogier Hintzen; Romain Marignier; Sven Jarius; John Marcelletti; Terry J Smith; Michael R Yeaman; May H Han; Orhan Aktas; Metha Apiwattanakul; Brenda Banwell; Denis Bichuetti; Simon Broadley; Philippe Cabre; Tanuja Chitnis; Jerome De Seze; Kazuo Fujihara; Benjamin Greenberg; Kerstin Hellwig; Raffaele Iorio; Sven Jarius; Eric Klawiter; Ingo Kleiter; Marco Lana-Peixoto; Kevin O'Connor; Jacqueline Palace; Friedman Paul; Naraporn Prayoonwiwat; Klemens Ruprecht; Olaf Stuve; Thomas Tedder; Silvia Tenembaum; Juan P Garrahan; Buenos Aires; Katja van Herle; Danielle van Pelt; Pablo Villoslada; Emmanuelle Waubant; Brian Weinshenker; Dean Wingerchuk; Jens Würfel; Scott Zamvil
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-07-23

9.  Development of an Aquaporin-4 Orthogonal Array of Particle-Based ELISA for Neuromyelitis Optica Autoantibodies Detection.

Authors:  Francesco Pisani; Paolo Settanni; Stefania Rosito; Maria Grazia Mola; Raffaele Iorio; Carla Tortorella; Maddalena Ruggieri; Maria Trojano; Maria Svelto; Antonio Frigeri; Grazia Paola Nicchia
Journal:  PLoS One       Date:  2015-11-24       Impact factor: 3.240

Review 10.  Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system.

Authors:  Nese Sinmaz; Tina Nguyen; Fiona Tea; Russell C Dale; Fabienne Brilot
Journal:  J Neuroinflammation       Date:  2016-08-30       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.